2026 Q1 -tulosraportti
Vain PDF
104 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenNice to see some progress today Then a reasonable financial report tomorrow and we'll go up a bit higher in price😊
remember that we came from low levels now, so no real reason to pop the champagne yet....- ·14 t sittenstock status The batch of Weeco Astrum 10/10 has still not been released, therefore everything is status quo. Stenocare's management must think that they have been under a lucky star in 2026. Firstly, because politicians, like a thief in the night, removed the subsidy for flower medicine as of July 10, 2026. Secondly, that there was so much chaos, both among doctors, pharmacies, and insurance companies, that not everyone had realized that the subsidy had been removed as of July 10, and that doctors were only allowed to prescribe cannabis oil for a maximum of 3 months' consumption (for insured persons). After July 10, not all doctors had realized that the subsidy had been removed, and continued to prescribe flower medicine to their patients. This was only possible because many of the insurance company's AOK members had also not understood it, and therefore the approval button was not deactivated. This was only activated on July 29, as is known, when the clarification of the law, from July 10, was published. Subsequently, Weeco Astrum 10/10 sold out incredibly quickly, except in Hamburg, where there is a satellite warehouse. It went so quickly because doctors prescribed 2 X 30 ml. Weeco Astrum 10/10 as they usually did, and people redeemed two bottles at a time, therefore the entire market was quickly swept clean of the most popular oils. On August 13, a new announcement came that doctors may only prescribe medicine for a maximum of 3 months' consumption. So after the 13th, doctors have only been able to prescribe one bottle at a time, as this corresponds to approx. 2 -3 months' consumption. To summarize why I believe Stenocare must feel they have been under a lucky star throughout 2026. If there hadn't been chaos after July 10, doctors would immediately have prescribed oils instead of flowers. Thus, all of Germany would have been drained, and there would not be medicine for everyone due to the strict rules for stock. But because those people who had understood the message and rushed to hoard flowers, they ensured, without their knowledge, that there was oil for everyone, and when people's home stock runs out and they need oil instead, there would be a chance for the oil to be released before wave no. 2 hits Germany. For the last 4 quarters, management's smile has gone from ear to ear. But tomorrow I expect that we will see two where the smile is so wide that it hits the neck.
- ·1 päivä sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.htmlI just read in the French article from yesterday, which I shared, that the politicians very much want to have a decree ready by October 1st at the latest. Then I thought, does that mean that they will then be ready to legalize it, and the oils after this date will be on the shelves? The answer is no. If it succeeds, then this must happen subsequently. When a decree is signed by the president, the process enters a new epoch. HAS is an abbreviation of Haute Autorité de Santé (the French health authority) HAS must now assess each individual oil and extract individually. This is where Stenocare's Astrum 10/10 will be at the top of the pile of applications. It is naturally also in this phase that companies like Stenocare can officially submit their specific products for approval in the health insurance system. Stenocare has outsourced this process to their partner ICMF (Institut des Cannabinoïdes Médicaux Français) in France. The last part of the process is that HAS must determine the exact price of the approved products, as well as how much the French health insurance funds must pay in subsidies to the patients. In France, one can get 100% reimbursement, we can only cross our fingers that Astrum 10/10 will get this status, just like in Germany. The French politicians and authorities are striving for everything to be finished and approved by the beginning of 2027. but as long as it's not set in stone, anything can happen.
- ·1 päivä sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?
It is always difficult to predict financial reports. I myself hope for more than 3 mil in Q2, preferably close to 4 mio dkk,-. Also, preferably some news regarding expansion in Germany and if they can already tell a bit about France. Always remember that the Share price and the company (this applies to all companies) are not necessarily connected. Share price development is 100% driven by investors' expectations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
104 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenNice to see some progress today Then a reasonable financial report tomorrow and we'll go up a bit higher in price😊remember that we came from low levels now, so no real reason to pop the champagne yet....
- ·14 t sittenstock status The batch of Weeco Astrum 10/10 has still not been released, therefore everything is status quo. Stenocare's management must think that they have been under a lucky star in 2026. Firstly, because politicians, like a thief in the night, removed the subsidy for flower medicine as of July 10, 2026. Secondly, that there was so much chaos, both among doctors, pharmacies, and insurance companies, that not everyone had realized that the subsidy had been removed as of July 10, and that doctors were only allowed to prescribe cannabis oil for a maximum of 3 months' consumption (for insured persons). After July 10, not all doctors had realized that the subsidy had been removed, and continued to prescribe flower medicine to their patients. This was only possible because many of the insurance company's AOK members had also not understood it, and therefore the approval button was not deactivated. This was only activated on July 29, as is known, when the clarification of the law, from July 10, was published. Subsequently, Weeco Astrum 10/10 sold out incredibly quickly, except in Hamburg, where there is a satellite warehouse. It went so quickly because doctors prescribed 2 X 30 ml. Weeco Astrum 10/10 as they usually did, and people redeemed two bottles at a time, therefore the entire market was quickly swept clean of the most popular oils. On August 13, a new announcement came that doctors may only prescribe medicine for a maximum of 3 months' consumption. So after the 13th, doctors have only been able to prescribe one bottle at a time, as this corresponds to approx. 2 -3 months' consumption. To summarize why I believe Stenocare must feel they have been under a lucky star throughout 2026. If there hadn't been chaos after July 10, doctors would immediately have prescribed oils instead of flowers. Thus, all of Germany would have been drained, and there would not be medicine for everyone due to the strict rules for stock. But because those people who had understood the message and rushed to hoard flowers, they ensured, without their knowledge, that there was oil for everyone, and when people's home stock runs out and they need oil instead, there would be a chance for the oil to be released before wave no. 2 hits Germany. For the last 4 quarters, management's smile has gone from ear to ear. But tomorrow I expect that we will see two where the smile is so wide that it hits the neck.
- ·1 päivä sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.htmlI just read in the French article from yesterday, which I shared, that the politicians very much want to have a decree ready by October 1st at the latest. Then I thought, does that mean that they will then be ready to legalize it, and the oils after this date will be on the shelves? The answer is no. If it succeeds, then this must happen subsequently. When a decree is signed by the president, the process enters a new epoch. HAS is an abbreviation of Haute Autorité de Santé (the French health authority) HAS must now assess each individual oil and extract individually. This is where Stenocare's Astrum 10/10 will be at the top of the pile of applications. It is naturally also in this phase that companies like Stenocare can officially submit their specific products for approval in the health insurance system. Stenocare has outsourced this process to their partner ICMF (Institut des Cannabinoïdes Médicaux Français) in France. The last part of the process is that HAS must determine the exact price of the approved products, as well as how much the French health insurance funds must pay in subsidies to the patients. In France, one can get 100% reimbursement, we can only cross our fingers that Astrum 10/10 will get this status, just like in Germany. The French politicians and authorities are striving for everything to be finished and approved by the beginning of 2027. but as long as it's not set in stone, anything can happen.
- ·1 päivä sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?It is always difficult to predict financial reports. I myself hope for more than 3 mil in Q2, preferably close to 4 mio dkk,-. Also, preferably some news regarding expansion in Germany and if they can already tell a bit about France. Always remember that the Share price and the company (this applies to all companies) are not necessarily connected. Share price development is 100% driven by investors' expectations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
104 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenNice to see some progress today Then a reasonable financial report tomorrow and we'll go up a bit higher in price😊remember that we came from low levels now, so no real reason to pop the champagne yet....
- ·14 t sittenstock status The batch of Weeco Astrum 10/10 has still not been released, therefore everything is status quo. Stenocare's management must think that they have been under a lucky star in 2026. Firstly, because politicians, like a thief in the night, removed the subsidy for flower medicine as of July 10, 2026. Secondly, that there was so much chaos, both among doctors, pharmacies, and insurance companies, that not everyone had realized that the subsidy had been removed as of July 10, and that doctors were only allowed to prescribe cannabis oil for a maximum of 3 months' consumption (for insured persons). After July 10, not all doctors had realized that the subsidy had been removed, and continued to prescribe flower medicine to their patients. This was only possible because many of the insurance company's AOK members had also not understood it, and therefore the approval button was not deactivated. This was only activated on July 29, as is known, when the clarification of the law, from July 10, was published. Subsequently, Weeco Astrum 10/10 sold out incredibly quickly, except in Hamburg, where there is a satellite warehouse. It went so quickly because doctors prescribed 2 X 30 ml. Weeco Astrum 10/10 as they usually did, and people redeemed two bottles at a time, therefore the entire market was quickly swept clean of the most popular oils. On August 13, a new announcement came that doctors may only prescribe medicine for a maximum of 3 months' consumption. So after the 13th, doctors have only been able to prescribe one bottle at a time, as this corresponds to approx. 2 -3 months' consumption. To summarize why I believe Stenocare must feel they have been under a lucky star throughout 2026. If there hadn't been chaos after July 10, doctors would immediately have prescribed oils instead of flowers. Thus, all of Germany would have been drained, and there would not be medicine for everyone due to the strict rules for stock. But because those people who had understood the message and rushed to hoard flowers, they ensured, without their knowledge, that there was oil for everyone, and when people's home stock runs out and they need oil instead, there would be a chance for the oil to be released before wave no. 2 hits Germany. For the last 4 quarters, management's smile has gone from ear to ear. But tomorrow I expect that we will see two where the smile is so wide that it hits the neck.
- ·1 päivä sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.htmlI just read in the French article from yesterday, which I shared, that the politicians very much want to have a decree ready by October 1st at the latest. Then I thought, does that mean that they will then be ready to legalize it, and the oils after this date will be on the shelves? The answer is no. If it succeeds, then this must happen subsequently. When a decree is signed by the president, the process enters a new epoch. HAS is an abbreviation of Haute Autorité de Santé (the French health authority) HAS must now assess each individual oil and extract individually. This is where Stenocare's Astrum 10/10 will be at the top of the pile of applications. It is naturally also in this phase that companies like Stenocare can officially submit their specific products for approval in the health insurance system. Stenocare has outsourced this process to their partner ICMF (Institut des Cannabinoïdes Médicaux Français) in France. The last part of the process is that HAS must determine the exact price of the approved products, as well as how much the French health insurance funds must pay in subsidies to the patients. In France, one can get 100% reimbursement, we can only cross our fingers that Astrum 10/10 will get this status, just like in Germany. The French politicians and authorities are striving for everything to be finished and approved by the beginning of 2027. but as long as it's not set in stone, anything can happen.
- ·1 päivä sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?It is always difficult to predict financial reports. I myself hope for more than 3 mil in Q2, preferably close to 4 mio dkk,-. Also, preferably some news regarding expansion in Germany and if they can already tell a bit about France. Always remember that the Share price and the company (this applies to all companies) are not necessarily connected. Share price development is 100% driven by investors' expectations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt